Folgen
Keine Story von Sanofi Pasteur MSD GmbH mehr verpassen.

Sanofi Pasteur MSD GmbH

Filtern
  • 07.04.2016 – 09:03

    GARDASIL® 9: 2-dose Schedule Approved in Europe

    Lyon, France (ots/PRNewswire) - The European Commission granted marketing authorization for a two-dose schedule in 9-14 year old girls and boys for GARDASIL®9, the 9-valent HPV vaccine Sanofi Pasteur MSD announced today that the European Commission has approved a 2-dose schedule for adolescent girls and boys aged 9 to 14 for GARDASIL®9, its 9-valent Human Papillomavirus (HPV) vaccine, for use in the 31 countries ...

  • 19.02.2016 – 09:02

    Vaxelis®, New Fully-liquid Paediatric Hexavalent Vaccine Approved in the European Union

    Lyon, France (ots/PRNewswire) - This decision opens the way to making Vaxelis® available to infants and toddlers in European countries Sanofi Pasteur MSD announced today that the European Commission has granted the marketing authorization for Vaxelis®, a new fully-liquid hexavalent vaccine indicated for primary and booster vaccination of infants and toddlers from the ...

  • 17.09.2015 – 09:01

    Sanofi Pasteur MSD Welcomes the Publication of a Special Issue on the Economic Value of Vaccination

    Lyon, France (ots/PRNewswire) - A relevant and comprehensive approach on the benefits of vaccines on healthcare systems sustainability and economic growth   Sanofi Pasteur MSD is proud to announce the publication of a supplement dedicated to the economic value of vaccination in the Journal of Market Access and Health Policy. The series of 7 articles has been developed ...

  • 17.06.2015 – 09:02

    Sanofi Pasteur MSD : GARDASIL®9: New HPV Vaccine Approved in the European Union

    Lyon, France (ots/PRNewswire) - The European Commission grants marketing authorization for GARDASIL 9, the only 9-valent HPV vaccine Sanofi Pasteur MSD announced today that the European Commission has granted marketing authorization for GARDASIL 9. GARDASIL 9 is a 9-valent HPV vaccine for active immunization of females and males from the age of 9 years against ...

  • 20.04.2015 – 09:02

    Sanofi Pasteur MSD Welcomes the 10 year Anniversary

    Lyon, France (ots/PRNewswire) - European vaccine leader hosts events across the region to help raise awareness of immunization throughout life Sanofi Pasteur MSD welcomes the World Health Organization's European Immunization Week 2015 (EIW 2015) with a series of awareness-raising events across the region, taking place between April 20th and 25th. Sanofi Pasteur MSD, a European leader for vaccines in Europe, has joined ...

  • 05.03.2015 – 09:02

    European Commission Grants "2+1 Immunization Schedule" for Hexyon® 6-in-1 Paediatric Vaccine

    Lyon, France (ots/PRNewswire) - This decision opens the way to making Hexyon(R) available to more infantsin European countries Sanofi Pasteur MSD announced today that the European Commission has granted a new vaccination schedule of the 6-in-1 paediatric vaccine Hexyon(R) (DTaP-IPV-HB-Hib vaccine) for a "2+1" schedule of administration, in addition to other possible ...

  • 22.04.2014 – 09:01

    Sanofi Pasteur MSD Welcomes European Immunization Week 2014

    Lyon, France (ots/PRNewswire) - European vaccine leader hosts events across the region to help raise awareness of immunization throughout life Sanofi Pasteur MSD welcomes the World Health Organization's European Immunization Week 2014 (EIW 2014) with a series of awareness-raising events across the region, taking place between April 22nd and 26th. Sanofi Pasteur MSD, the European leader for vaccines in Europe, has joined ...

  • 27.02.2014 – 09:02

    Gardasil®: New 2-dose Schedule Granted Positive CHMP Opinion for Europe's Leading HPV Vaccine

    Lyon, France (ots/PRNewswire) - European Committee for Medicinal Products for Human Use evaluated positively a 2-dose schedule for Gardasil(R) in adolescents Sanofi Pasteur MSD announced today that its quadrivalent HPV vaccine, Gardasil(R) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the ...

  • 11.07.2013 – 09:02

    First Baby Vaccinated with Hexyon® in Europe

    Lyon, France (ots/PRNewswire) - Germany first market in Europe to use innovative 6-in-1 paediatric vaccine Two month old baby Ben from Mönchengladbach, Germany, is the first infant in Europe to receive the new 6-in-1 paediatric vaccine Hexyon(R) from Sanofi Pasteur MSD. Hexyon is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against six priority diseases: diphtheria, tetanus, whooping cough, ...

  • 22.04.2013 – 07:31

    Hexyon[TM] 6-in-1 Paediatric Vaccine Approved in Europe

    Lyon, France (ots/PRNewswire) - Hexyon is Europe's only fully liquid, ready-to-use hexavalent paediatric vaccine Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur in Europe, announced today that the European Commission has granted a community marketing authorisation for Hexyon[TM], an innovative new 6-in-1 paediatric vaccine. Hexyon[TM] is the only fully liquid, ready-to-use 6-in-1 vaccine to protect ...

  • 11.04.2013 – 08:54

    Sanofi Pasteur MSD Submits Quadrivalent Influenza Vaccine for European Licences

    Lyon, France (ots/PRNewswire) - - Addition of fourth influenza virus strain aims to increase protection against influenza - Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, announced today that it has submitted a decentralized marketing authorization application in Europe for a 'Quadrivalent' influenza vaccine, a new advanced seasonal flu vaccine. ...

  • 22.02.2013 – 13:02

    European Medicines Agency Recommends Approval of Hexyon 6-in-1 Paediatric Vaccine

    Lyon, France (ots/PRNewswire) - Upon approval Hexyon will be the only fully liquid, ready-to-use 6-in-1 paediatric vaccine in Europe Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur in Europe, announced today that their innovative 6-in-1 paediatric vaccine Hexyon has been recommended for marketing authorisation by the European Medicines Agency's ...

  • 14.01.2013 – 08:02

    Sanofi Pasteur MSD's Andrea Rappagliosi Appointed President of Vaccines Europe

    Lyon, France (ots/PRNewswire) - Appointment marks new chapter in vaccine advocacy in Europe Andrea Rappagliosi, Vice President of Market Access, Health Policy & Medical Affairs at Sanofi Pasteur MSD has been appointed President of Vaccines Europe as of 1st January 2013. Vaccines Europe is the group representing vaccine manufacturers within the European Federation of ...

  • 06.12.2012 – 10:03

    Studies Demonstrate Gardasil® Has Long Duration of Protection From HPV Disease

    Lyon, France (ots/PRNewswire) - Data represents the largest follow-up available for an HPV vaccine Data from two large, long term follow-up studies continue to show that vaccination with Gardasil offers a long duration of protection from human papillomavirus (HPV) diseases related to HPV types 6, 11, 16 and 18. HPV-related diseases include cervical cancer and genital ...

  • 19.10.2012 – 13:01

    Sanofi Pasteur MSD to Commercialise New 6-in-1 Paediatric Vaccine in European Markets

    Lyon, France (ots/PRNewswire) - Vaccine submitted to European Medicines Agency for licence review Sanofi Pasteur MSD plans to licence and commercialise an innovative 6-in-1 paediatric vaccine in its European territories. The new hexavalent vaccine, developed by Sanofi Pasteur, is the only fully liquid, ready to use ...